WO2003010185A3 - Method for making acylated polypeptides - Google Patents
Method for making acylated polypeptides Download PDFInfo
- Publication number
- WO2003010185A3 WO2003010185A3 PCT/DK2002/000501 DK0200501W WO03010185A3 WO 2003010185 A3 WO2003010185 A3 WO 2003010185A3 DK 0200501 W DK0200501 W DK 0200501W WO 03010185 A3 WO03010185 A3 WO 03010185A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptides
- certain
- lysine
- host cells
- transformed host
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 5
- 239000002243 precursor Substances 0.000 abstract 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- 239000004472 Lysine Substances 0.000 abstract 2
- 238000003776 cleavage reaction Methods 0.000 abstract 2
- 230000007017 scission Effects 0.000 abstract 2
- 102400000321 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 102400000324 Glucagon-like peptide 1(7-37) Human genes 0.000 abstract 1
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 abstract 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000010933 acylation Effects 0.000 abstract 1
- 238000005917 acylation reaction Methods 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention is related to a method of producing polypeptides in transformed host cells by expressing a precursor molecule of the desired polypeptide which is to be acylated in a subsequent in vitro step. The precursor molecule comprises an N-terminal extension has a cleavage site different from lysine for cleavage from the desired polypeptide. The invention is also related to DNA-sequences, vectors and transformed host cells for use in the claimed method. Further, the present invention is related to certain precursors of the desired polypeptides and certain acylation methods. The invention provides a method for making polypeptides being preferentially acylated in certain lysine ϵ-amino groups. Specifically, glucagon like protein-1 (GLP-1(7-37)) is used.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02750841A EP1421102A2 (en) | 2001-07-24 | 2002-07-18 | Method for making acylated polypeptides |
| JP2003515544A JP2005503141A (en) | 2001-07-24 | 2002-07-18 | Methods for making acylated polypeptides |
| AU2002355160A AU2002355160A1 (en) | 2001-07-24 | 2002-07-18 | Method for making acylated polypeptides |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200101140 | 2001-07-24 | ||
| DKPA200101140 | 2001-07-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2003010185A2 WO2003010185A2 (en) | 2003-02-06 |
| WO2003010185A3 true WO2003010185A3 (en) | 2004-03-25 |
Family
ID=8160636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/DK2002/000501 WO2003010185A2 (en) | 2001-07-24 | 2002-07-18 | Method for making acylated polypeptides |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1421102A2 (en) |
| JP (1) | JP2005503141A (en) |
| AU (1) | AU2002355160A1 (en) |
| WO (1) | WO2003010185A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006108270A1 (en) | 2005-04-11 | 2006-10-19 | Pharmagap Inc. | Inhibitors of protein kinases and uses thereof |
| CA2659958A1 (en) * | 2005-08-05 | 2007-02-15 | Pharmagap Inc. | Peptides targeted to protein kinase c isoforms and uses thereof |
| EP1872790A1 (en) | 2006-06-26 | 2008-01-02 | DeveloGen Aktiengesellschaft | New formulation for increasing bioavailability of neurturin |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995035384A1 (en) * | 1994-06-17 | 1995-12-28 | Novo Nordisk A/S | N-terminally extended proteins expressed in yeast |
| EP0712862A2 (en) * | 1994-11-17 | 1996-05-22 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
| US5905140A (en) * | 1996-07-11 | 1999-05-18 | Novo Nordisk A/S, Novo Alle | Selective acylation method |
| US6011007A (en) * | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| WO2000055119A1 (en) * | 1999-03-17 | 2000-09-21 | Novo Nordisk A/S | Method for acylating peptides and novel acylating agents |
-
2002
- 2002-07-18 WO PCT/DK2002/000501 patent/WO2003010185A2/en active Application Filing
- 2002-07-18 AU AU2002355160A patent/AU2002355160A1/en not_active Abandoned
- 2002-07-18 JP JP2003515544A patent/JP2005503141A/en not_active Withdrawn
- 2002-07-18 EP EP02750841A patent/EP1421102A2/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011007A (en) * | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| WO1995035384A1 (en) * | 1994-06-17 | 1995-12-28 | Novo Nordisk A/S | N-terminally extended proteins expressed in yeast |
| EP0712862A2 (en) * | 1994-11-17 | 1996-05-22 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
| US5905140A (en) * | 1996-07-11 | 1999-05-18 | Novo Nordisk A/S, Novo Alle | Selective acylation method |
| WO2000055119A1 (en) * | 1999-03-17 | 2000-09-21 | Novo Nordisk A/S | Method for acylating peptides and novel acylating agents |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002355160A1 (en) | 2003-02-17 |
| JP2005503141A (en) | 2005-02-03 |
| WO2003010185A2 (en) | 2003-02-06 |
| EP1421102A2 (en) | 2004-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR950702947A (en) | A METHOD AND A COMPOSITION FOR PREPARING CONCRETE ELEMENTS HAVING REMARKABLE COMPRESSIVE RESISTANCE AND FRACTURE ENERGY, AND ELEMENTS OBTAINED THEREBY | |
| WO2004113493A3 (en) | Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site | |
| WO2004067706A3 (en) | Production of multimeric proteins | |
| DE69535931D1 (en) | Process, construct and conjugate for making multiple nucleic acid copies | |
| JP2001527387A (en) | Synthetic leader peptide sequence | |
| WO2006017325A3 (en) | Aav vector compositions and methods for enhanced expression of immunoglobulins the same | |
| WO2003014318A3 (en) | Methods for treating diabetes and other blood sugar disorders | |
| CA2454264A1 (en) | A method of producing insulinotropic glp-1 (7-36) polypeptide and/or glp-1 analogs | |
| WO2007011975A3 (en) | Methods to express recombinant proteins from lentiviral vectors | |
| AU2002310321A1 (en) | Compositions and methods for high-level, large-scale production of recombinant proteins | |
| WO2003010186A3 (en) | Method for making acylated polypeptides | |
| WO2003010185A3 (en) | Method for making acylated polypeptides | |
| JPH029390A (en) | Hirudin variant, its use and production | |
| WO2004007537A3 (en) | Modified adenoviral fiber with ablated to cellular receptors | |
| AU6177101A (en) | In vitro evolution of nucleic acids and encoded polypeptide | |
| AU7873798A (en) | N-terminally extended proteins expressed in yeast | |
| WO2002016611A3 (en) | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders | |
| ATE503003T1 (en) | METHOD FOR PRODUCING RECOMBINANT POLYPEPTIDES | |
| WO2002004630A3 (en) | Methods for recombinatorial nucleic acid synthesis | |
| WO2003042354A3 (en) | Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis | |
| KR950014721B1 (en) | Method for coating of zirconia-alumina composite | |
| EP0818537A3 (en) | Method for cloning and producing the sapI restriction endonuclease in E. coli | |
| ATE319837T1 (en) | METHOD FOR PRODUCING RECOMBINANT TRYPSIN | |
| WO2004026251A3 (en) | Process for decreasing aggregate levels of pegylated protein | |
| ATE162853T1 (en) | HUMAN RECOMBINANT PLACENTAL RIBONUCLEASE INHIBITOR AND METHOD FOR PRODUCING |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG UZ VN YU ZA ZM Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2002750841 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2003515544 Country of ref document: JP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2002750841 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |